Array BioPharma, Inc. (NASDAQ:ARRY)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases.

Recs

0
Player Avatar JorgeAura (< 20) Submitted: 12/6/2012 7:47:31 PM : Outperform Start Price: $3.62 ARRY Score: +1.50

The best pipeline portfolio of market.

Featured Broker Partners


Advertisement